| Literature DB >> 31024232 |
Roshini Prakash1, Sivan Izraely2, Nikita S Thareja1, Rex H Lee1, Maya Rappaport2, Riki Kawaguchi3, Orit Sagi-Assif2, Shlomit Ben-Menachem2, Tsipi Meshel2, Michal Machnicki1, Shuichi Ohe4, Dave S Hoon4, Giovanni Coppola3, Isaac P Witz2, S Thomas Carmichael1.
Abstract
Neural repair after stroke involves initiation of a cellular proliferative program in the form of angiogenesis, neurogenesis, and molecular growth signals in the surrounding tissue elements. This cellular environment constitutes a niche in which regeneration of new blood vessels and new neurons leads to partial tissue repair after stroke. Cancer metastasis has similar proliferative cellular events in the brain and other organs. Do cancer and CNS tissue repair share similar cellular processes? In this study, we identify a novel role of the regenerative neurovascular niche induced by stroke in promoting brain melanoma metastasis through enhancing cellular interactions with surrounding niche components. Repair-mediated neurovascular signaling induces metastatic cells to express genes crucial to metastasis. Mimicking stroke-like conditions in vitro displays an enhancement of metastatic migration potential and allows for the determination of cell-specific signals produced by the regenerative neurovascular niche. Comparative analysis of both in vitro and in vivo expression profiles reveals a major contribution of endothelial cells in mediating melanoma metastasis. These results point to a previously undiscovered role of the regenerative neurovascular niche in shaping the tumor microenvironment and brain metastatic landscape.Entities:
Keywords: angiogenesis; astrocytosis; gliosis; neuroblast; stroke
Year: 2019 PMID: 31024232 PMCID: PMC6465799 DOI: 10.3389/fnins.2019.00297
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
FIGURE 1The regenerative neurovascular niche after stroke facilitates brain metastasis. (A) Representative brain images from control and stroke groups subjected to melanoma metastasis shown in the top panel. GFP+ cells identifies brain metastatic melanoma at high magnification in the bottom panel. (B) Schematics showing region from stroke brains and corresponding regions in control quantified. (C) Bar graphs of total number of metastatic cells in both control and stroke groups and (D) showing quantification and distribution of metastatic cells in different brain regions as mean ± SEM (n = 6–7, four sections per animal, ∗∗p = 0.0082, ∗∗∗p = 0.0012 Mann–Whitney, two-tailed t-test). PV-WM, periventricular white matter; ST, striatum; OB, olfactory bulb; SVZ, subventricular zone; RMS, rostral migratory stream; HF, hippocampus. (E) Representative images depicting vascular density in control and hypoxia + metastasis group. (F) Box and scatter plots with minimum and maximum percentage vascular density (surface area μm3) mean ± SEM (n = 6–8), (∗∗p = 0.0090 unpaired, two-tailed t-test) (G) Stroke increases. brain metastasis significantly more than hypoxia mediated angiogenesis. Bar graphs showing number of metastatic foci in stroke and hypoxic groups shown as mean ± SEM (n = 6–8, four sections/animal, ap = 0.003, Mann–Whitney, two-tailed t-test). (H) Representative images from days 1 and 7 after stroke showing localization of fluorescent microspheres in green and vasculature (PECAM) in red. (I) Box and scatter plots with minimum and maximum percentage volume of fluorescent microspheres localized to the peri-infarct and contralateral regions at days 1 and 7 after stroke, mean ± SEM (n = 5–6, one-way ANOVA, Holm-Sidak for multiple comparisons p = 0.46, ns, non-significant). (J) Schematics of the method of quantification of fluorescent microspheres volume localized around the peri-infarct regions. (K,L) Representative immunohistochemical images and intensity of endogenous albumin extravasated from days 1 and 7 after stroke and contralateral regions, mean ± SEM (n = 5, three regions/animal, ∗p = 0.0255, one-way ANOVA, Holm-Sidak for multiple comparisons).
FIGURE 2Repair augments direct cellular interactions between the metastatic cell and neurovascular niche. (A) Immunohistochemical analysis of metastatic melanoma cells shown as GFP+ green, lectin-labeled vasculature in white and DCX+ neuroblasts in red. (B) Quantitative analysis of metastatic cell interaction with vessels associated with or without neuroblasts shown as scatter plot with mean ± SEM (n = 5–8, four sections/animal, aap < 0.0001; bp = 0.0354, Kruskal–Wallis, one-way ANOVA, Dunn’s for multiple comparisons). (C) Representative brain images of metastatic foci (GFP+) and neuroblasts (RFP+) over time (left). Control groups did not associate with neuroblasts in the corresponding brain region. Schematic representation of distance bins (25 μm intervals) used to analyze neuroblast distribution around metastatic foci. Bin closest to melanoma is shown in bright red and increasing distances showing in gradients of yellow and the farthest depicted in gray (right). (D) Box and scatter plot showing number of neuroblast contact surfaces interacting with metastatic foci. Mean ± SEM (n = 6–9, ∗∗p = 0.0092, ∗∗∗∗p = 0.0006, aap < 0.0001; one-way ANOVA, Holm-Sidak post hoc test used for multiple comparisons). (E) Bubble plot depicting density and distribution of neuroblasts around metastatic foci at 25 μm distances Mean ± SEM (n = 5–8, bp = 0.033, cp = 0.033, ∗p < 0.0164; one-way ANOVA, Holm-Sidak post hoc test used for multiple comparisons). Bubble size represents number of neuroblasts and increasing distances are color coded as shown in schematic.
FIGURE 3Repair enhances direct cellular interactions between the metastatic cell and astrocytes and increases neovascularization. (A) Representative images showing metastatic melanoma interaction with reactive astrocytes during melanoma extravasation. (B) Quantitative analysis of % volume of metastatic cell extravasated. Mean ± SEM [∗∗∗p = 0.0082, aap < 0.0001, two-way ANOVA, Holm-Sidak post hoc test used for multiple comparisons (n = 5–8)]. (C) Astrocyte coverage at corresponding time points around each metastatic foci. Mean ± SEM [aap < 0.0001, ap = 0.0006, two-way ANOVA, Holm-Sidak post hoc test used for multiple comparisons (n = 5–8)]. (D) Methodology of analysis of neovascularization and infection point analysis. (E) Changes in neovascularization response over time mean ± SEM, (n = 5–8), (∗p = 0.0424, ∗∗p = 0.0349, ap = 0.0454, bp = 0.0015, cp = 0.0163, dp = 0.0474, ep = 0.0009, two-way ANOVA, Fisher LSD). (F) Bar graphs showing temporal changes in inflection point ratios [∗p = 0.0032, ∗∗p = 0.0215; ∗∗∗p = 0.0012; aap < 0.0001; two-way ANOVA, Holm-Sidak post hoc test used for multiple comparisons, (n = 5–8)].
FIGURE 4Human brain metastatic melanoma interact with neuroblasts and astrocytes. (A) Representative image depicting characterization of antibodies on human brain samples. Human hippocampus section showing staining for DCX, PSA-NCAM, GFAP, and Tuc-4. DCX positive neuroblasts colocalize with Tuc-4. (B) Schematics showing human brain tumor margin immunostained for neuroblasts and astrocyte association. (C) Immunohistochemical representative images of brain metastatic melanoma show novel interactions with neuroblasts excised from human patients (4/15 show close neuroblast–melanoma interactions). (D) Representative images of brain metastatic melanoma from human patients show interactions with astrocytes.
FIGURE 5(A) Schematic representation of tissue processing and FACS sort methodology performed. (B) Gating areas used during FACS and the GFP and MCSP-PE double positive cells were isolated for RNA sequencing. MCSP, melanoma-associated chondroitin sulfate proteoglycan.
FIGURE 6Molecular signaling systems in regeneration-potentiated brain metastasis. (A) Schematic representation of flow of transcription profiling and regenerative neurovascular niche components interacting with metastatic cells. Significant and differentially expressed genes between regeneration-potentiated and contralateral metastatic cells as determined by log2 fold change > 0.5 and p < 0.05 (Stroke-MET). (B) Top differentially regulated canonical pathways with largest negative logP shown in metastatic melanoma cells from the regenerative neurovascular niche compared to contralateral tissue. The dashed line represents the ratio of the number of molecules in the dataset over the number of molecules in the pathway. (C) Volcano plot showing p-values correlated with log2 fold change in metastatic cells isolated from regenerative neurovascular niche vs. contralateral side. Genes systematically identified from top pathways from (B), are marked in blue. (D,E) GSEA of hallmark genes up and downregulated in the Stroke-MET transcriptome. Estimated probability of FDR < 25% represent 3/4 chances of a gene set being valid.
Functionally relevant gene identified from Stroke-MET transcriptome.
| Gene | Log2 FC | Pathways regulated ( | Reported function(s) (database used: pubmed) | References |
|---|---|---|---|---|
| NTNG1 | -1.922 | Axon guidance | Axonal growth protein also expressed in stroma of human PDAC. | |
| High methylation status associated with poor outcomes in colorectal cancer. | ||||
| Promote axon outgrowth. | ||||
| Unreported in brain metastasis | ||||
| HHIP | -1.775 | Axon guidance | Regulates endothelial cell proliferation/migration through Hedgehog pathway inhibition | |
| Gli-Hedgehog signaling enhances melanoma proliferation | ||||
| Methylated in pancreatic cancer | ||||
| Decreases VEGF-mediated tumor angiogenesis | ||||
| Down-regulated during tumor angiogenesis in human tumors | ||||
| IGF1 | 1.458 | Axon guidance, fibrosis | Enhances survival of breast cancer brain metastasis. | |
| IGF promotes EMT and stemness via NANOG and STAT3 signaling (melanoma brain metastasis) | ||||
| IGF-1 supports tumor proliferation in melanoma metastasis. | ||||
| GAB1 | 1.489 | Axon guidance, neuropathic pain, phagosome formation, Tec kinase, leukocytes, role of macrophages, fibroblasts, and endothelial cells, Rho family, thrombin signaling, aldosterone signaling | Mediates tumor angiogenesis in melanoma through Akt and ERK1/2 pathways. | |
| GAB1 upregulation promotes tumor cell invasion, migration via CXCR4 and tumor growth. | ||||
| GAB1 enhances vascular sprouting via VEGF-induced eNOS activation. | ||||
| GNA14 | 1.935 | Axon guidance, ephrin receptor signaling, Tec kinase, Rho family, thrombin signaling | Inhibits cell differentiation and enhances tumorigenicity after TNFa stimulation | |
| Activates STAT3 signaling, NF-kB and Ras-dependent pathways | ||||
| CXCR4 | 2.175 | Axon guidance, ephrin receptor signaling, leukocytes | Highly expressed in brain metastases across cancer types (breast, lung, kidney, colon, ovary, prostate, and thyroid). | |
| Activation of CXCR4-CXCL12 axis enhance tumor cell migration. | ||||
| CXCR4 disrupts vascular permeability through PI3K-AKT and FAK pathway. | ||||
| CXCR4 induces growth and metastasis of cancers including melanoma regardless of organ specificity | ||||
| RAC2 | 2.711 | Axon guidance, ephrin receptor signaling, leukocytes | Rac2 promotes melanoma metastasis and tumor angiogenesis. | |
| Rac2 activates SDF-1/CXCR4 system | ||||
| GRIA4 | -1.966 | Neuropathic pain | GLUR4 knockdown enhances cell viability and proliferation, while stimulating cancer cell migration (through upregulation of MMP2 and integrins) | |
| Found to be hypermethylated in cancers (follicular lymphoma/oropharyngeal squamous cell carcinoma) compared to benign lesions | ||||
| GluR4 signaling activates MAPK and K-ras signaling (decreasing threshold of K-ras induced oncogenic signaling) in pancreatic cancer lesions | ||||
| Downregulated in glioma cells. | ||||
| RND2 | -1.746 | Phagosome formation, Rho family, thrombin signaling | Downregulated in melanoma compared to melanocytes | |
| Enhances melanoma susceptibility to low dose cisplatin treatment through PARP cleavage and activation. | ||||
| Aza treatment sensitizes melanoma cells to therapeutics by upregulating RND2. | ||||
| RHOV | 2.88 | Phagosome formation, Tec kinase, Rho family, thrombin signaling | Overexpressed in lung cancer and NSCLC lines | |
| Signal transducer for PAK6, protein kinase implicated in prostate cancer chemoresistance | ||||
| JAK3 | 1.468 | Tec kinase | Activates STAT5A | |
| Activates PD-L1 antitumor suppression in melanoma cells | ||||
| Promotes squamous cell carcinoma migration and proliferation | ||||
| Expressed at higher levels in brain metastases of melanoma compared to primary melanoma | ||||
| FRK | 1.627 | Tec kinase | Causes PTEN deregulation and is overexpressed in melanoma | |
| Enhances tumor progression in cell-type specific manner | ||||
| STAT5A | 2.211 | Tec kinase | Enhances cell viability, proliferation, and growth. | |
| STAT5a inhibition enhances cisplatin susceptibility. | ||||
| Activated in melanoma cells by EGFR and JAK1 and SRC | ||||
| Active STAT5a signaling induces EMT and CSC markers and promotes metastasis in prostate cancer | ||||
| PIP5KL1 | -1.805 | Aldosterone signaling, Rho family | PIP5KL1 upregulation suppresses tumor cell proliferation, migration, and growth. | |
| Overexpression of PIP5KL1 markedly inhibited ( | ||||
| PIP5KL1 transduction induces apoptotic changes in 293T cells | ||||
| GATA3 | -1.525 | Thrombin signaling | GATA3 suppression promotes EMT, metastasis and suppresses cell differentiation and alters the tumor microenvironment by inducing angiogenesis in breast cancer. | |
| Genomic analyses reveal a high frequency target mutation of GATA3 in breast cancer, melanomas, clear cell sarcoma and poor prognosis. | ||||
| GATA3 is a negative regulator of tumor invasion and growth. | ||||
| Ectopic GATA3 ablates canonical TGF-β-Smad signaling axis. | ||||
| DKK1 | -4.852 | Role of macrophages, fibroblasts, and endothelial cells | DKK1 is hypermethylated in several cancer types. | |
| 3 DKK1 protein secretion abrogated in melanoma however reported in breast, prostate and lung cancer lines. | ||||
| 4 DKK1 suppresses melanoma cell invasion. | ||||
| 5 Temsirolimus (mTOR inhibitor) potentiates temozolomide (second line treatment for brain cancers) in metastatic melanoma by DKK1 pathway. | ||||
| FRZB | -1.783 | Role of macrophages, fibroblasts, and endothelial cells | Hypermethylated in melanoma and methylation promotes melanoma migration and invasion. | |
| FRZB reverses EMT in pancreatic cancer. | ||||
| IL32 | -1.746 | Role of macrophages, fibroblasts, and endothelial cells | IL-32α administration prevents human melanoma proliferation through p21, p53 and TRAILR1. | |
| STAT1 and IL-32 signaling mediates immunoresponse upon TLR2/6 agonists and IFN-gamma treatment in melanoma. | ||||
| IRAK2 | 1.696 | Role of macrophages, fibroblasts, and endothelial cells | IRAK2 and LAMP1 are negatively regulated by miR-373. | |
| Novel role of IRAK2, RAF6, and Ras in p38 MAPK activation. | ||||
| Highly expressed in malignant melanomas. | ||||
| C5 | 1.528 | Role of macrophages, fibroblasts, and endothelial cells | C5a promotes the development and growth of melanoma (targeted melanoma therapy using complement-inhibitory drugs). | |
| C5a inhibition blocks tumor progression and angiogenesis. | ||||
| CLDN1 | -2.537 | Leukocytes | Claudin-1 acts as a metastasis suppressor, and loss of claudin-1 is positively correlated with poor outcomes in lung adenocarcinoma. | |
| Claudin-1 prevents brain metastasis of melanoma. | ||||
| Decreased expression in vessels associated with melanocytic neoplasms. | ||||
| CTNNA2 | -1.483 | Leukocytes | Deleted in MEL10 and predicted to be a tumor suppressor. | |
FIGURE 7OGD alters chemokine/cytokine responses in the neurovascular niche and enhances migration of brain metastatic cells. (A) Schematics showing the interaction of human astrocytes (h-Astro) and human endothelial cells (h-EC) with metastatic melanoma cells. (B) Schematics of method of oxygen glucose deprivation (OGD) conditioned media exposed to metastatic melanoma cells. (C) Migratory response of metastatic melanoma cells exposed to OGD conditioned media from cells are shown as mean ± SD, ∗P < 0.05. (D,E) Heatmap of relative expression of secreted proteins profiled from the medium of h-Astro (E) and h-EC (D). Functionally grouped enriched pathways are shown in one color. Enrichment/depletion tests performed with ClueGO application on cytoscape, κ score ≥ 0.4.
FIGURE 8Oxygen-glucose deprivation (OGD) affects viability of human-endothelial cells (h-EC), astrocytes (h-Astro) and adhesion of metastatic melanoma cells. (A,B) Percentage viability of h-EC (A) and h-Astro (B) subjected to OGD for 4 h followed by a 4, 20, and 44 h reperfusion phase. Cell viability as measured by XTT assay. The bars represent the average % viability of OGD exposed cells, normalized to control cells subjected to normal oxygen and glucose levels, mean ± SD, ∗p < 0.05. The different time points indicate the hours in reperfusion after OGD/control conditions. (C) h-EC were subjected to OGD for 4 h followed by a 20 h reperfusion phase. m-Cherry expressing macro- and micro-metastatic melanoma cells were seeded on top of the h-EC monolayer and incubated for 30 min, to allow adhesion to occur. The fluorescence signal of labeled cells was measured before and after removal of non-adherent cells. The bars represent the % adherent cells in the wells. The graph represents an average of three independent experiments + SD. ∗P < 0.05. (D) m-Cherry expressing metastatic melanoma cells were seeded on top of the OGD or control h-EC monolayers and incubated for 30 min with 5 μg/mL VCAM-1 blocking Ab, an isotype control (mIgG1), or without IgG. The fluorescence signal of labeled cells was measured before and after removal of non-adherent cells. The bars represent % adherent melanoma cells seeded with anti-VCAM-1 blocking Ab or isotype control normalized to % adherent melanoma cells seeded without Ab. The graph represents an average of two independent experiments + SD. ∗p < 0.05.
FIGURE 9Overlapping transcription landscapes from regenerative NV niche after stroke and melanoma brain metastasis. (A,B) Common canonical signaling pathways between the in vivo Stroke-MET and in vitro OGD-ECMET/OGD-AstroMET transcriptome. (C,D) Rank–rank hypergeometric overlap (RRHO) analysis of common genes expression spread between Stroke-MET and OGD-ECMET/OGD-AstroMET transcriptome. RRHO analysis of common genes expression spread between Stroke-MET and OGD-AstroMET datasets. Red and blue pixels on the heatmap depict a high and low number of overlapping genes, respectively. Stroke-MET and OGDEC-MET display stronger hypergeometric overlap those with OGDAstro-MET transcriptome. (E,F) Overlapping up and downregulated genes between in vivo Stroke-MET and in vitro OGD-ECMET/OGD-AstroMET transcriptome are depicted in the Venn diagram. (G–J) Heatmap of log2 FC of overlapping genes between Stroke-MET and OGD-ECMET/OGD-AstroMET transcriptome. The up and down regulated overlapping genes are shown in red and blue a change in gradients of these color correspond to the level of log2 FC as shown on the scale bars. Genes classified based on the cellular location and the color coded as shown in the key at the bottom of the heatmaps : Blue: extracellular, green: plasma membrane, orange: cytoplasm, violet: nucleus, and black: other.
FIGURE 10Gene expression changes in OGD exposed metastatic melanoma cells. (A) The effect of OGD exposed astrocyte secreted factors on melanoma gene expression. Astrocytes were subjected to OGD or control conditions for 4 h followed by a 20 h reperfusion phase. Metastatic melanoma cells were treated for 24 h with the OGD or control conditioned media collected from the reperfusion phase. Total RNA was extracted and gene expression was determined by RT-qPCR. mRNA expression levels were normalized to the expression of RS9. Bars represent gene expression in cells treated with conditioned medium of “stroked” astrocytes normalized to gene expression in cells treated with control astrocyte conditioned medium mean ± SD of three independent experiments, ∗p < 0.05, ∗∗p < 0.01. (B) Primer sequences used for the qPCR analysis shown in (A,B).
FIGURE 11Astrocyte–metastatic cell and endothelial cell–metastatic cell interactome. Extracellular and plasma membrane bound proteins were chosen to determine putative gene interactions between metastatic melanoma cell with two cell types in the regenerative neurovascular niche–astrocyte/endothelial cells. Astrocyte–metastatic cell interactome display differentially expressed proteins in blue shows OGD exposed astrocyte secretome (blue panel) and their interactions with Genes in the metastatic melanoma cells from the Stroke-MET transcriptome colored in green (green panel). Endothelial cell–metastatic cell interactome differentially expressed proteins in red shows OGD exposed astrocyte secretome (red panel) and their interactions with genes in the metastatic melanoma cells from the Stroke-MET transcriptome colored in green (green panel). Yellow panels depicts molecules in the extracellular space. Molecules in yellow: secretome, red: OGD exposed endothelial cells, blue: OGD exposed astrocytes, green: stroke responsive melanoma Stroke-MET.
FIGURE 12Gene network analysis of highly repetitive classes of coordinated diseases and functions from the Stroke-MET transcriptome. Network of gene interactions representing genes associated with “cancer” (A), “Neurological disease and injury” (B), “Development” (C). Red: upregulated genes, blue: downregulated genes, and larger nodes: central and highly connected genes. Nodes shown in gradients of red and blue are up- and down-regulated, respectively. Centrality values are provided in the Table 2. Central genes with higher connectivity with neighboring genes are shown as larger nodes in each category.
Centrality values of differentially regulated genes.
| Disease Network Centralities | |||
|---|---|---|---|
| Degree | Eigenvector | Betweenness | |
| XP01 | 17 | 0.08596991 | 3300.861 |
| SMAD3 | 16 | 0.3436861 | 3565.8477 |
| snRNP | 15 | 0.012245474 | 2225.245 |
| collagen | 15 | 0.32417372 | 1237.3102 |
| Collagen type I | 12 | 0.31365713 | 1503.7742 |
| Focal adhesion kinase | 11 | 0.26898885 | 1088.7654 |
| COL1A1 | 11 | 0.3225594 | 504.3585 |
| Collagen type IV | 10 | 0.24174887 | 657.4651 |
| HSP90AB1 | 9 | 0.12958206 | 1337.7277 |
| p85 (pik3r) | 9 | 0.16082734 | 1101.0994 |
| APP | 56 | 0.6285145 | 14092.723 |
| TRAF6 | 17 | 0.26952243 | 2496.349 |
| Jnk | 14 | 0.19043593 | 2337.5176 |
| TAZ | 11 | 0.11805606 | 2943.962 |
| TCTN2 | 10 | 0.03490787 | 1265.8921 |
| RPTOR | 9 | 0.18103331 | 1985.5358 |
| TNF | 48 | 0.5610349 | 11893.423 |
| NFkB (complex) | 23 | 0.28850913 | 4632.912 |
| Akt | 21 | 0.30290568 | 5351.877 |
| CALM1 | 11 | 0.12641135 | 1627.4298 |
| Sfk | 9 | 0.21849017 | 400.375 |
| CSK | 9 | 0.16786034 | 1086.8019 |
| CCT7 | 9 | 0.02809526 | 1204.9857 |
FIGURE 13Unique molecular signaling systems in brain metastasis. (A) Schematic representation of brain and distant sites of metastasis compared. The significant and differentially expressed genes between Brain metastasis (stroke responsive metastatic cells) and distant metastasis (liver metastasis) were compared. (B) Unique extracellular and plasma membrane genes that interact with the surrounding niche in each of these two transcriptomes were identified at FPKM values > 4. (C) Top canonical pathways differentially regulated in brain metastatic melanoma over a distant metastatic site (liver) with the largest negative logP values are shown. The dashed line represents the ratio of the number of molecules in the dataset over the number of molecules in the pathway. (D,E) GSEA of hallmark genes up and downregulated in the differentially expressed genes of brain metastatic vs. liver metastasis.